Cempra Inc., of Chapel Hill, N.C., presented at the Association for Research in Vision and Ophthalmology meeting in Baltimore data highlighting topical ophthalmic formulations of solithromycin in preclinical models of activity, tolerability and pharmacokinetics in the eye.